Summit Securities Group
NVCR icon

Summit Securities Group’s NovoCure NVCR Stock Holding History

Summit Securities Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$33.8K Buy
+2,117
New +$35.3K ﹤0.01% 639
2025
Q2 		– Sell
-232
Closed -$4.13K – 1316
2025
Q1 		$4.13K Buy
+232
New +$5.27K ﹤0.01% 625
2024
Q2 		– Sell
-251
Closed -$4K – 714
2024
Q1 		$4K Buy
+251
New +$3.69K ﹤0.01% 379

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Quantinno Capital Management
Quantinno Capital Management New York $106B AUM 29.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Summit Securities Group's NVCR Position: Q3 2026 in Review

Summit Securities Group opened a new position in NovoCure (NVCR) in Q3 2026: 2,117 shares worth $33.8K. The stake represents ﹤0.01% of the portfolio and ranks #639 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in NVCR as recently as Q1 2025.

Summit Securities Group first reported a position in NVCR in Q1 2024 and has held it in 3 quarters since. 183 funds tracked by Wall St. Rank hold NVCR as of Q3 2026.

  • Summit Securities Group held 2,117 shares of NovoCure worth $33.8K as of Q3 2026.
  • NovoCure was a new Summit Securities Group position in Q3 2026.
  • NovoCure made up ﹤0.01% of Summit Securities Group's portfolio in Q3 2026, its #639 holding.
  • Summit Securities Group first reported a position in NovoCure in Q1 2024 and has held it in 3 quarters since.
  • 183 funds tracked by Wall St. Rank held NovoCure as of Q3 2026.

Based on Summit Securities Group's 13F filing for Q3 2026, filed 5 Nov 2026.